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Neuroblastoma, a malignant tumour of the sympathetic nervous
system, is the most common extracranial solid tumour of child-
hood (Gale et al, 1982). The clinical behaviour of neuroblastoma
varies from spontaneous regression to malignant progression. It
can also differentiate into a benign ganglioneuroma in some older
patients. Generally, favourable outcome is associated with young
age of diagnosis, but biological differences of the tumours in the
age groups appear to be very important as well (reviewed in
Brodeur, 1998).
A number of genetic alterations has been shown to be associated
with poor prognosis, and these have been used as genetic markers
of neuroblastoma. The two most important types of somatic abnor-
malities are deletion of the distal part of the short arm of chromo-
some 1 (1p), and amplification of the MYCN oncogene. Both
MYCN amplification and 1p deletion are associated with rapid
progression and poor prognosis (Seeger et al, 1985; Ambros et al,
1995; Caron et al, 1996). DNA content of neuroblastoma has been
shown to be associated with prognosis as well. Tumours with
increased DNA content (or ‘polyploid’ karyotype) is associated
with a favourable outcome in infants with neuroblastoma (Look
et al, 1991). Recently, focus has been directed towards a third
karyotypic abnormality in neuroblastoma tumours, i.e. extra copies
of the distal part of the long arm of 17 (17q gain). 17q gain is
defined as a structural rearrangement of chromosome 17, which
results in partial gain of 17q relative to 17p. This almost invariably
involves a breakpoint in 17q12–21 with gain of the distal portion
of the 17q arm (Lastowska et al, 1997a). Unbalanced translocation
resulting in loss of distal 1p and gain of 17q has previously been
identified by fluorescence in situ hybridization (FISH) in primary
tumours and neuroblastoma cell lines (Caron et al, 1994; Van Roy
et al, 1994). It was also demonstrated by Southern blot and cytoge-
netic analysis that the translocation very likely takes place in the
S/G2 phase (Caron et al, 1994). More recently, comparative
genomic hybridization (CGH) studies have shown that extra chro-
mosome 17q material occurs in approximately 70–80% of primary
tumours, either as gain of the whole chromosome 17 or the q arm
alone (Plantaz et al, 1997; Lastowska et al, 1998; Vandsompele et
al, 1998). Using FISH studies Meddeb et al (1996) and Lastowska
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et al (1997b) showed that 17q can translocate on to a number of
chromosome regions other than 1p, and that such rearrangements
also results in gain of 17q material. Meddeb et al (1996) reported
that among translocations only 17% were (1;17) translocations,
whereas the remainder involved various other chromosomes: chro-
mosome 4, 5, 6, 9, 11, 12, 14, 17 and 19. Moreover, both groups
found that 17q gain also showed correlation to poor prognosis. A
third study showed that 17q gain is associated with all established
indicators of poor prognosis; stage 4 disease, age above 1 year at
diagnosis, 1p deletion, MYCN amplification and diploidy/
tetraploidy (Lastowska et al, 1997a). Lastowska et al (1997a) and
Caron et al (1996) also found that 17q gain was associated with
poor outcome.
Somatostatin (SST; synonym name ‘somatotropin release
inhibitory factor’, SRIF), a growth hormone inhibitory substance,
is a multifunctional peptide that is distributed widely throughout
the central nervous system (CNS) and peripheral tissues (reviewed
in Bell et al, 1995; Patel et al, 1995). At cellular level, actions of
SST is involved in many different processes, including cell prolif-
eration (Patel et al, 1995). Recently, it was shown by
radioimmunoassay that somatostatin in neuroblastoma is associ-
ated with differentiation to benign ganglioneuroma in vivo and
favourable outcome in advanced tumours (Kogner et al, 1997).
The physiological actions of somatostatin are mediated by high-
affinity receptors on the surface of responsive cells that are
coupled by G proteins to a multiple effector system including
adenylyl cyclase, ion channels and tyrosine phosphatases. Five
somatostatin receptors subtypes, SSTR 1–5, have been cloned
(Yamada et al, 1992). The somatostatin receptor isoform 2 gene
(SSTR2) is mapped to 17q24 and encodes a 369 amino acid
membrane protein (Yamada et al, 1992). Recently, in vivo expres-
sion of SSTR2 in neuroblastoma tumours was shown to be corre-
lated with young age at diagnosis, localized clinical stage and
favourable outcome (Schilling et al, 1999). In another study,
Sestini et al (1996) found that SSTR2 expression in vitro was
negatively related to MYCN amplification and according to
Kaplan–Meier analysis positively related to survival. Interestingly,
Zhang and associates found a point mutation in the SSTR2 gene in
human small-cell lung cancer cell line COR-L103 (Zhang et al,
1995). The mutation caused loss of the C-terminal amino acid
residue number 182 of SSTR2.
The aims of this study were to investigate the occurrence of 17q
gain in the patient material of the Swedish neuroblastoma tumour
study group, and its relation to survival and poor prognostic
factors such as MYCN amplification, 1p deletion and diploid
DNA content. Moreover, the aims were to investigate the role of
the SSTR2 gene in neuroblastoma development and progression,
by screening of DNA from neuroblastoma tumours for possible
mutations in the SSTR2 gene.
MATERIALS AND METHODS
Patients
Tumour samples were obtained from 48 children with neuro-
blastoma of all different stages (Table 1). The children were staged
according to the International Neuroblastoma Staging System
criteria (INSS, Brodeur et al, 1993). Tumour cell content of the
samples was histologically assessed in adjacent tumour tissue to
that used for DNA extraction. All tumour specimens were used for
FISH analysis, and 43 from which DNA had been extracted were
used for polymerase chain reaction (PCR)-based SSCP/HD detec-
tion. Of these, 32 were sequenced for the SSTR2 gene. In previous
studies (Martinsson et al, 1995, 1997, and unpublished data),
MYCN amplification and 1p deletion have been detected for most
of the patients included in this study using FISH analysis and
PCR-based DNA polymorphisms.
Table 1. Summary of clinical parameters and experimental data from
patients with neuroblastoma compared to 17q gain
Patients Stage Sex 1p-del N-myc 17q gain Outcome Survival
84 1 F – – – N 97+
124 1 M nd – – N 61+
146 1 F – – – N 80+
156 1 M – – – N 75+
161 1 F – – – N 68+
181 1 F – – + N 47+
51 2A F – – – N 134+
121 2A M + – + D 96
177 2A M – – – N 13+
St156 2A F – – + N 2+
St124 2 M + – + A 26+
127 2B F – – + N 87+
138 2B M – – + N 79+
125 4S M nd – – N 89+
St142 4S M (+) + + D 0
69 3 M – – + D 17
85 3 F – – – N 98+
128 3 M nd nd – N 89+
135 3 M nd + + D 6
136 3 F nd + + D 11
153 3 F – – – N 74+
157 3 M – – – DOC 0
187 3 F – – + A 7+
St99 3 F + – + D 10
St100 3 F – – – N 47+
St131 3 M + + + L L
St164 3 M – + + A 7+
32 4 M – – + D 12
41 4 F – – + D 8
49 4 M nd nd – D 16
55 4 F + + + D 4
95 4 F + + + D 15
106 4 F + + + N 76+
107 4 M – – + D 10
112 4 M – – – D 18
114 4 F – – (+) D 25
123 4 F nd + + D 4
126 4 M – + + D 8
155 4 F + – – D 19
163 4 M + + + D 10
174 4 F + + + D 6
St102 4 M + + + D 11
St116 4 F – + – A 32+
St118 4 M – – + A 24+
St119 4 M + – (+) A 24+
St126 4 F – + + A 25+
St130 4 F (+) + + D 10
St153 4 M nd – + L L
Column 2: 1, 2A, 2B, 4S, 3 and 4, neuroblastoma stage; column 3: M, male;
F, female; column 4: 1p-del, 1p deletion based on short tandem repeat
polymorphism according to Martinsson et al, 1995; +, 1p deletion –, no 1p
deletion (+), unsure results; nd, not determined; column 5: +, N-myc
amplification; –, no amplification; nd, not determined; column 6: 17q gain,
additional material of 17q, +, 17q gain >10% of counted cells; –, no 17q gain;
(+), unsure results; column 7: N, no evidence of disease; D, dead of disease;
A, alive with disease; DOC, dead of surgical complications; L, lost for follow-
up; column 8: follow-up (months); +, alive at follow-up.PCR-amplification
Forward (F) and reverse (R) primers for the SSTR2 gene (17q24)
and marker D17S796 (17p) were synthesized using an ABI
Applied Biosystem 392 DNA/RNA Synthesizer. SSTR2 exon 1,
corresponding to the complete SSTR2 isoform 2a and approxi-
mately 94% of isoform 2b, and the alternatively spliced exon 2,
corresponding to the remainder of SSTR2 isoform 2b (Patel et al,
1993), was amplified in five pieces using primers according to
Table 2. Primer sequences for SSTR2 were selected using the
DNASTAR primer select software (Lasergene, Madison, WI,
USA) from the published cDNA sequences (GenBank accession
numbers M81830 and L13033). Primers for D17S796 were from
Dib et al (1996). Amplifications were carried out in 20-ml volume
containing 50–100 ng template DNA; 15 pmol of each primer;
10 mM Tris–HCl (pH 8.3); 30 mM potassium chloride; 1.5 mM
magnesium chloride; 0.001% (w/v) gelatin; 4.4 nmol of each
dATP, dCTP, dGTP, dTTP, and 0.25 U Taq DNA polymerase
(Pharmacia). Amplifications were performed with 30 standard
cycles of 30–45 s at 94°C, 30–45 s at 58°C and 60 s at 72°C.
Following the last cycle, an additional extension step was
performed for 7 min at 72°C. SSTR2–4 was amplified in 30 ml
volume containing 2.5 U Taq DNA polymerase with an initial
incubation at 95°C for 5 min.
Cytogenetic preparations
Touch prepared imprint slides from primary neuroblastoma
tumours were subjected to standard procedures of hypotonic treat-
ment (0.3% sodium chloride) for 10 min and fixation in increasing
concentrations of ethanol:acetic acid (vol. 3:1) solution.
Isolation of bacterial artificial chromosomes and
labelling of probes for FISH
The Human bacterial artificial chromosomes (BAC) DNA pool
library, purchased from Research Genetics Inc. (Huntsville, AL,
USA), was screened with PCR-assays using primers for marker
D17S796 (17p) and primers for the SSTR2 gene (17q24) respec-
tively (Table 2). The BAC-DNA was extracted and purified using
QIAGEN Plasmid Purification kit. The 17q-BAC (43–C7) was
labelled with Cy3-dCTP and the 17p-BAC (146-G1) was labelled
with FluoroX-dCTP with nick translation according to FluoroLink
Cy3 Nick Translation Kit (Amersham Life Science). The labelled
BAC-DNAs were used as FISH probes on touch prepared imprint
slides.
Fluorescence in situ hybridization
The probes used were Cy3 labelled BAC 43-C7 (17q24, giving a
red signal), FluoroX labelled marker BAC 146-G1 (17p, giving a
green signal), and digoxigenin/FITC-labelled p53 (17p13.1,
giving a green signal) from Oncor. The probes were hybridized to
metaphase chromosome control slides and to interphase slides
from primary NB tumours. Slides were dehydrated in ethanol
series, and denatured in sodium hydroxide (NaOH) solution (0.6%
NaOH, 70% ethanol). The interphase slides were pre-washed in
70% acetic acid for 30 s, and dehydrated in both ethanol and
acetone. BAC-probes were denatured for 10 min at 73°C in
hybridization buffer (50% formamide, 10% dextran sulphate, 2 ´
SSC (standard saline citrate), final pH 7.0) and pre-hybridized
in the presence of a 50-fold excess of Cot-1 DNA (Life
Technologies) for 2 h at 37°C. The 17p-digoxygenin probe was
pre-warmed at 37°C for 5 min. Ten microlitrss of each probe was
applied to slides in mixtures and hybridization was performed
under a 25 ´ 25 mm coverslip in a moist chamber at 37°C
overnight.
After hybridization, slides were washed in 2 ´ SSC at 50°C.
Slides hybridized with 17p-digoxygenin probe were immuno-
chemically stained with fluorescein isothiocyanate (FITC)-conju-
gated anti-digoxygenin antibody (Oncor) under a coverslip in a
moist chamber at 37°C for 20 min. DNA was stained in
0.25 mg ml–1 4,6-Diamidino-2-Phenylindole (DAPI, Sigma) in
Na2HPO4-buffer, pH 7.0, and an anti-fade solution containing 2%
1,4 diazabicyclo-(2,2,2) octane (DABCO, Sigma), 69% glycerol, 2
mM Tris–HCl, pH 8.0, and 0.9 mg ml–1 p-phenylenediamine (PPD,
Sigma) was applied. The preparations were examined with a Zeiss
Axiophot microscope with appropriate filters, photographed with
a computer-driven IMAC-CCD colour camera and modified with
the Meta system (Meta systems, Hard & Software GmbH, D68804
Altlussheim, Germany).
SSCP/HD
The SSCP/HD electrophoreses were run on 20% homogeneous
Phast gels with buffer system of native strips in Tris–tricin (0.2 M
Tris, 0.2 M tricin) at 15°C, 400 V, 5.0 mA, 1.0 W for 250 AVh on a
Phast system (Pharmacia Biotech). The Phast gels were pre-run
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Table 2 PCR primers used in this study
Exon Primer Sequence aPosition Length of
5¢–3¢ fragment (bp)
1 SSTR2-1FP CTG GAA CTA GCC TAA GAC TGA AAA 53–76 294
SSTR2-1RP TGC GAT GGC CAG GTT GAG 346–329
SSTR2-2FP GAA GAC CAT CAC CAA CAT TTA CAT 304–337 333
SSTR2-2RP CTC CGG AGC CCA GCA TA 636–620
SSTR2-3FP ATG ATC ACC ATG GCT GTG T 563–581 350
SSTR2-3RP ACG TTG AAT ATG TAG AAG GGA AGC 912–889
SSTR2-4FP ATC GTG GTG GCT GTC TTC 860–877 345
SSTR2-4RP CCC CCA AGC AGT TCA GA 1204–1188
2 SSTR2-5FP TTG AAT GAT AAT GTG CTA A 7–25 276
SSTR2-5RP CAT ACT CGA ATT TGC TAC T 282–264
a Exon 1, GenBank accession number M81830; alternatively spliced exon 2, GenBank accession number L13033.at 400 V, 5.0 mA, 1.0 W for 10–15 AVh. PCR-products were
diluted two- to threefold with a formamide-dye solution containing
98% formamide, 0.05% xylene cyanol, 0.05% bromophenol blue,
and 20 mM EDTA. The reaction mixtures were denatured for 5 min
at 98°C, and approximately 1.0 ml of each sample was loaded on
the gel. The Phast-gels were developed using Bio-Rad silver-stain
(Bio-Rad Laboratories).
DNA-sequencing
Sequencing was performed using either an ABI Prism 377 DNA
Sequencer or an ABI Prism 310 Genetic Analyzer (Perkin-Elmer).
The sequencing reactions were made using ABI Prism Big Dye
Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer).
The PCR-products were purified with QIAquick Spin PCR purifi-
cation kit (QIAGEN), and the concentration of the PCR-products
were estimated by comparison to a 100 bp-mass ladder on a 2%
agarose gel. The sequence reactions were performed with 25 stan-
dard cycles of 45 s at 95°C, 45 s at 55°C and 180 s at 60°C using
approximately 70 ng PCR-product and primers SSTR2-1FP,
SSTR2-2FP, SSTR2-3RP, SSTR2-4RP, SSTR2-5RP respectively
(Table 2). The sequence reaction products were precipitated with
ethanol and the pellets were diluted in ‘loading buffer’ (5 vol.
deionized formamide, 1 vol. 25 mM EDTA, pH 8.0, blue dextran)
when using ABI Prism 377 DNA Sequencer or in ‘Template
Suppression reagent’ TSr (Perkin-Elmer) when using ABI Prism
310 Genetic Analyzer. Before loading, the samples were denatured
for 3 min at 95°C on a thermo block. The sequence reaction
products, using ABI Prism 377 DNA Sequencer, were loaded on a
7% acrylamide gel.
RESULTS
Detection of 17q gain with FISH analysis
Tumour samples from patients with neuroblastoma (n = 48, Table
1) were subjected to FISH analysis with probes for chromosome
17 (Figure 1). The 17p probes, BAC 146-G1 or p53 (Oncor), were
used as references to the 17q probe (BAC 43-C7, 17q24), to
distinguish 17q gain from trisomy, tetrasomy and polysomy of the
complete chromosome 17. Forty to 100 cells were counted from
each patient, except for case 114 and St119 where only 25 cells
could be counted. All tumours were informative for all probes. 17q
gain was defined as additional material in more than 10% counted
cells, +. 17q gain was found in 31 out of 48 neuroblastoma
tumours, whereas two of these (case 114 and St119) were defined
as uncertain 17q gain patients, (+), due to the small amount of
informative cells (Table 1). Most of the 17q gain tumours showed
one additional signal of 17q, i.e. two 17p signals and three 17q
signals (2+3), but some also showed two or more additional
signals of 17q (2+4, 2+5) (Figure 1). Many of the tumours from
patients with lower stages of neuroblastoma showed tetrasomy or
polysomy for chromosome 17. Only six patients, five with 17q
gain (3+4, 3+5) and one without (3+3), showed trisomy for
chromosome 17. Five showed monosomy of 17p (1+3).
Analysis of 17q gain and prognosis
17q gain was found more frequently in patients with stage 4 (17
out of 21) compared with other stages combined (14 out of 26, P =
0.028 Fisher’s exact test, Table 1). Only one of the patients with
stage 1 showed 17q gain. Five out of seven of the patients with
stage 2 (stage 2A and 2B) had 17q gain, while seven out of the 11
patients with stage 3 had additional material of 17q. Forty-five out
of 48 children were evaluated for survival probability in relation to
17q gain. Two children were lost for follow-up and one died of
surgical complications, and were therefore not included. Forty
children had tumours informative for all three prognostic factors,
i.e. 1p-deletion, MYCN amplification and 17q gain, and these
results are displayed in the Venn diagrams (Figure 2). Children
with tumours of all different stages showing 17q gain had a worse
outcome, 18 of 29 dead of disease versus three of 16 among those
with tumours with no 17q gain. Survival probability according to
Kaplan–Meier was also better for those with no 17q gain, 78.6% at
5 years from diagnosis compared to 34.3% for those with 17q gain
(P = 0.0009, Mantel–Haentzel log-rank test, Figure 2A). Children
with tumours at favourable stage (stage 1, 2, 3 and 4S) showing
17q gain had a significantly worse outcome, six of 13 dead of
disease versus zero of 12 among those with tumours showing no
17q gain. Thus, the survival probability of low-stage tumours
showing no 17q gain was 100% at 5 years from diagnosis
compared to 52.5% for those showing 17q gain (P = 0.0021,
Mantel–Haentzel log-rank test, Figure 2B). As displayed in the
Venn-diagram no low-stage tumour showed 1p-deletion or MYCN
amplification without concomitant 17q gain (Figure 2B). Children
with high-stage tumours (stage 4) showing 17q gain had no signif-
icantly worse outcome, 12 of 16 dead of disease versus three of
four among those with tumours showing no 17q additional mate-
rial (Figure 2C).
Mutation detection of the SSTR2 gene with PCR-based
SSCP/HD and sequencing
Tumour samples from patients with neuroblastoma (n = 43), were
subjected to PCR-based SSCP/HD analysis for SSTR2 exon 1
(data not shown). Twenty-two of the 43 neuroblastomas were stage
4 tumours, ten were stage 3 tumours and nine were of unknown
stages. The SSTR2 exon 1 was amplified from tumour DNA and
normal DNA in four overlapping parts, giving approximately
300–350 bp long fragments (Figure 3). SSCP patterns from
tumour DNA of patients were compared with SSCP patterns from
the patients constitutional DNA (prepared from blood lympho-
cytes) and that of control DNA subsequently sequenced.
Generally, most of the SSCP pattern generated from the same
SSTR2 fragment were identical, and did not diverge notably from
normal controls. Sequencing was carried out for the complete
SSTR2 cDNA sequence (i.e. exon 1 and alternatively spliced exon
2, Figure 3) for 18 PCR-samples, while an additional 14 tumour
samples were partially sequenced (1–4 fragments of the total 5
fragments). All sequenced were compared to the SSTR2 sequence
derived from the genome database (GenBank accession numbers
M81830 and L13033), and none of them showed any deviation
from the reference sequence.
DISCUSSION
Neuroblastoma is an extremely heterogeneous disease, and a
number of genetic and cytogenetic alterations have shown to asso-
ciate with prognosis. In the present study, FISH was used to study
status of chromosome 17q in 48 neuroblastoma tumours. 17q gain
Role of chromosome arm 17q in neuroblastoma 1405
British Journal of Cancer (1999) 81(8), 1402–1409 © 1999 Cancer Research Campaignwas detected in 65% of the neuroblastoma tumours. Moreover,
17q gain was found to be associated with poor prognostic factors
such as deletion of chromosome arm 1p and amplification of the
MYCN oncogene. These findings are supported by earlier studies
(Lastowska et al, 1997a; Plantaz et al, 1997). The association
between 1p deletion and 17q gain is not surprising since physical
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Figure 1 Representative FISH analyses of normal cells (A–B) and neuroblastoma tumour cells (C–H). (A) Metaphase chromosomes 17q 24 (BAC 43–C7):
red/17p13.1 (p53): green. (B) Metaphase chromosomes 17p (BAC 146-G1): green. (C) 17q gain (3+4) interphase cell, case 138, 17q: red/17p:green. (D) 17q
gain (2+3, 2+4) interphase cells, case 95, 17q: red/17p: green. (E) 17q gain (2+3, 2+4) interphase cells, case 121, 17q: red/17p: green. (F) 17q gain (2+3)
interphase cell, case St118, 17q: red/17p:green. (G) 17q gain (2+3) interphase cell, case 136, 17q: red/17p: green. (H) Interphase cell showing polysomy for
chromosome 17, case 84, 17q: red/17p: green. The digital images were captured and modified using Meta Systems (Meta Systems, Hard & Software GmbH,
D68804 Altlussheim, Germany)connection between these chromosomes has been seen in the form
of unbalanced translocations der(1)t(1p;17q) (Caron et al, 1994;
Van Roy et al, 1994; Meddeb et al, 1996; Lastowska et al, 1997a,
1997b). These translocations result in loss of 1p and gain of 17q,
and are thought to occur in the S/G2 phase of the cell cycle (Caron
et al, 1994). In the present study, FISH was only carried out on
interphase cells, and therefore the frequency of such translocation
could not be investigated. The association between MYCN
Role of chromosome arm 17q in neuroblastoma 1407
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Figure 2 Survival probability according to Kaplan–Meier (left) combined with Venn diagrams (right) of the relationship between the prognostic factors 1p-
deletion, MYCN amplification, and 17q gain in neuroblastoma patients. (A) Survival probability for children with all stages of neuroblastoma; with 17q gain
(solid line) and without 17q-gain (dashed line). (B) Survival probability for children with tumours of favourable stages 1, 2, 3, and 4S. (C) Survival probability for
children with neuroblastoma stage 4 tumours. Only patients informative for all prognostic factors were used in the Venn diagramsamplification and 17q gain is more difficult to explain. There are
some few cases where MYCN HSRs are flanked by 17q material
(Van Roy et al, 1994; Lastowska et al, 1997a). But such rearrange-
ments are not generally seen in primary tumours, where MYCN
amplifies mainly in the form of double minute chromosomes
(Lastowska et al, 1997a). As found in the present study and in
earlier reports, all these three alterations; 1p-deletion, MYCN
amplification, and 17q gain, show strong association to each other.
This gives rise to speculations whether they are structurally related
in some kind of way. Like two earlier studies (Meddeb et al, 1996;
Lastowska et al, 1997a) we also found that the number of 17q gain
(31 out of 48 analysed neuroblastomas) exceeded the number of
1p deletions (14/40) and the number of MYCN amplifications
(16/46). But not all of the 1p deletions and MYCN amplifications
status were determined in this study, which has to be taken into
account. Nevertheless, these results indicate that 1p deletion and
MYCN amplification could be secondary events of 17q gain as a
primary event.
In the present study most of the 17q gain tumours showed 1
additional signal of 17q (2+3), but 36% of the 17q gain tumours
also showed two or more additional signals (2+4, 2+5) of 17q
(Figure 1). This gave rise to questions about 17q gain being a
dose-dependent feature. However, in this study no differences in
survival probability between patients showing one additional 17q
signal in relation to patients showing two or more additional 17q
signals in the tumour specimens could be seen.
In the present study, five patients who died of disease had 17q
gain without 1p deletion and MYCN amplification (cases 69, 32,
41, 107 and 114; Table 1), but there were also a number of patients
surviving with no evidence of disease that showed 17q gain (e.g.
cases 181, St156, 127, 138 and 106). However, from the data it
was clear that children with tumours of all different stages
showing 17q gain had a significantly worse outcome, 18 of 29
dead of disease versus three of 16 among those with tumours with
no 17q additional material. Survival probability according to
Kaplan–Meier was also better for those with no 17q gain, 75% at
5 years from diagnosis compared to 34% for those with 17q gain
(P = 0.0009, Figure 2A). Remarkably, among children with low-
stage tumours (stage 1, 2, 3 and 4S) only those showing 17q gain
died of disease (six of six), whereas none of those showing no 17q
gain died from disease (P = 0.0021, Figure 2B). In contrast, chil-
dren with high-stage tumours (stage 4) showing 17q gain had no
significantly worse outcome, 12 of 16 dead of disease versus three
of four among those with tumours showing no 17q additional
material. These results suggest that 17q gain as a prognostic factor
plays a more crucial role in low-stage tumours, and that metastic
stage 4 tumours display many other adverse prognostic factors
(1p-deletions, MYCN amplifications, etc.) which somehow
surpass the effect of 17q gain. As seen in the Venn-diagram no
low-stage tumour and only two of the high-stage tumours showed
1p-deletion or MYCN amplification without showing 17q gain as
well (Figure 2B). This supports the hypothesis of 17q gain as a
primary genetic event.
Two studies, one by in vivo detection with 111In-pentetreotide
scintigraphy (Schilling et al, 1998) and one by in vitro detection
with competitive reverse transcription PCR (RT-PCR) (Sestini et
al., 1996), have shown that expression of SSTR2 in neuroblastoma
tumours is positively related to survival and negatively related to
poor prognosis. A point mutation in the SSTR2 gene, causing loss
of 182 C-terminal amino acid residues of SSTR2, has earlier been
detected in a human small-cell lung cancer carcinoma (Zhang et al,
1995). In the present study we wanted to investigate whether the
low level of SSTR2 expression in unfavourable neuroblastomas is
a primary genetic event as described for the point mutation in the
SSTR2 gene in small-cell lung cancer. Screening of 43 neuro-
blastoma tumours for mutations in the SSTR2 gene was carried
out with PCR-based SSCP/HD and sequencing. We found that all
SSCP patterns were normal compared to the wild-types, and no
mutations could be detected in the SSTR2 gene of the 32 success-
fully sequenced patients as a contrast to the reported SSTR2 gene
mutation earlier detected in a colon cancer cell line (Zhang et al,
1995). This suggests that mutations in the SSTR2 gene is
uncommon in neuroblastoma tumours and not related to the 17
gain often seen in these.
In conclusion, the neuroblastoma patients analysed in this study
have a high incidence of 17q gain in agreement with what have
been reported by other groups. 17q gain is associated with poor
prognosis and with other prognostic factors. No mutations could
be detected in the SSTR2 gene that explains its reported low
expression in high-stage neuroblastoma.
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